Rajendra Prasad Bandari1, Zongrun Jiang2, Tamila Stott Reynolds3, Nicole E Bernskoetter1, Ashley F Szczodroski4, Kurt J Bassuner5, Daniel L Kirkpatrick5, Tammy L Rold6, Gary L Sieckman4, Timothy J Hoffman7, James P Connors5, Charles J Smith8. 1. Research Service, Truman VA, Columbia, MO 65201, USA; Department of Radiology, University of Missouri School of Medicine, Columbia, MO 65211, USA. 2. Research Service, Truman VA, Columbia, MO 65201, USA; Department of Chemistry, University of Missouri, Columbia, MO 65211, USA. 3. Research Service, Truman VA, Columbia, MO 65201, USA; Department of Veterinary Pathobiology, University of Missouri College of Veterinary Medicine, Columbia, MO 65211, USA. 4. Research Service, Truman VA, Columbia, MO 65201, USA. 5. Department of Radiology, University of Missouri School of Medicine, Columbia, MO 65211, USA. 6. Research Service, Truman VA, Columbia, MO 65201, USA; Department of Internal Medicine, University of Missouri School of Medicine, Columbia, MO 65211, USA. 7. Research Service, Truman VA, Columbia, MO 65201, USA; Department of Internal Medicine, University of Missouri School of Medicine, Columbia, MO 65211, USA; Department of Chemistry, University of Missouri, Columbia, MO 65211, USA. 8. Research Service, Truman VA, Columbia, MO 65201, USA; Department of Radiology, University of Missouri School of Medicine, Columbia, MO 65211, USA; University of Missouri Research Reactor Center, University of Missouri, Columbia, MO 65211, USA. Electronic address: smithcj@health.missouri.edu.
Abstract
UNLABELLED: Gastrin-releasing peptide receptors (GRPr) and prostate-specific membrane antigen (PSMA) are two identifying biomarkers expressed in very high numbers on prostate cancer cells and could serve as a useful tool for molecular targeting and diagnosis of disease via positron-emission tomography (PET). The aim of this study was to produce the multipurpose, bivalent [DUPA-6-Ahx-((64)Cu-NODAGA)-5-Ava-BBN(7-14)NH2] radioligand for prostate cancer imaging, where DUPA = (2-[3-(1,3-dicarboxypropyl)-ureido]pentanedioic acid), a small-molecule, PSMA-targeting probe, 6Ahx = 6-aminohexanoic acid, 5-Ava = 5-aminovaleric acid, NODAGA = [2-(4,7-biscarboxymethyl)-1,4,7-(triazonan-1-yl)pentanedioic acid] (a derivative of NOTA (1,4,7-triazacyclononane-1,4,7-triacetic acid)), and BBN(7-14)NH2 = bombesin, a GRPr-specific peptide targeting probe. METHODS: The PSMA/GRPr dual targeting ligand precursor [DUPA-6-Ahx-K-5-Ava-BBN(7-14)NH2], was synthesized by solid-phase and manual peptide synthesis, after which NODAGA was added via manual conjugation to the ε-amine of lysine (K). The new bivalent GRPr/PSMA targeting vector was purified by reversed-phase high performance liquid chromatography (RP-HPLC), characterized by electrospray-ionization mass spectrometry (ESI-MS), and metallated with (64)CuCl2 and (nat)CuCl2. The receptor binding affinity was evaluated in human, prostate, PC-3 (GRPr-positive) and LNCaP (PSMA-positive) cells and the tumor-targeting efficacy determined in severe combined immunodeficient (SCID) and athymic nude mice bearing PC-3 and LNCaP tumors. Whole-body maximum intensity microPET/CT images of PC-3/LNCaP tumor-bearing mice were obtained 18 h post-injection (p.i.). RESULTS: Competitive binding assays in PC-3 and LNCaP cells indicated high receptor binding affinity for the [DUPA-6-Ahx-((nat)Cu-NODAGA)-5-Ava-BBN(7-14)NH2] conjugate. MicroPET scintigraphy in PC-3/LNCaP tumor-bearing mice indicated that xenografted tumors were visible at 18h p.i. with collateral, background radiation also being observed in non-target tissue. CONCLUSIONS: DUPA-6-Ahx-((64)Cu-NODAGA)-5-Ava-BBN(7-14)NH2] targeting vector, as described herein, is the first example of a dual GRPr-/PSMA-targeting radioligand for molecular of imaging prostate tumors. Detailed in vitro studies and microPET molecular imaging investigations of [DUPA-6-Ahx-((64)Cu-NODAGA)-5-Ava-BBN(7-14)NH2 in tumor-bearing mice indicate that further studies are necessary to optimize uptake and retention of tracer in GRPr- and PSMA-positive tissues. Published by Elsevier Inc.
UNLABELLED: Gastrin-releasing peptide receptors (GRPr) and prostate-specific membrane antigen (PSMA) are two identifying biomarkers expressed in very high numbers on prostate cancer cells and could serve as a useful tool for molecular targeting and diagnosis of disease via positron-emission tomography (PET). The aim of this study was to produce the multipurpose, bivalent [DUPA-6-Ahx-((64)Cu-NODAGA)-5-Ava-BBN(7-14)NH2] radioligand for prostate cancer imaging, where DUPA = (2-[3-(1,3-dicarboxypropyl)-ureido]pentanedioic acid), a small-molecule, PSMA-targeting probe, 6Ahx = 6-aminohexanoic acid, 5-Ava = 5-aminovaleric acid, NODAGA = [2-(4,7-biscarboxymethyl)-1,4,7-(triazonan-1-yl)pentanedioic acid] (a derivative of NOTA (1,4,7-triazacyclononane-1,4,7-triacetic acid)), and BBN(7-14)NH2 = bombesin, a GRPr-specific peptide targeting probe. METHODS: The PSMA/GRPr dual targeting ligand precursor [DUPA-6-Ahx-K-5-Ava-BBN(7-14)NH2], was synthesized by solid-phase and manual peptide synthesis, after which NODAGA was added via manual conjugation to the ε-amine of lysine (K). The new bivalent GRPr/PSMA targeting vector was purified by reversed-phase high performance liquid chromatography (RP-HPLC), characterized by electrospray-ionization mass spectrometry (ESI-MS), and metallated with (64)CuCl2 and (nat)CuCl2. The receptor binding affinity was evaluated in human, prostate, PC-3 (GRPr-positive) and LNCaP (PSMA-positive) cells and the tumor-targeting efficacy determined in severe combined immunodeficient (SCID) and athymic nude mice bearing PC-3 and LNCaPtumors. Whole-body maximum intensity microPET/CT images of PC-3/LNCaPtumor-bearing mice were obtained 18 h post-injection (p.i.). RESULTS: Competitive binding assays in PC-3 and LNCaP cells indicated high receptor binding affinity for the [DUPA-6-Ahx-((nat)Cu-NODAGA)-5-Ava-BBN(7-14)NH2] conjugate. MicroPET scintigraphy in PC-3/LNCaPtumor-bearing mice indicated that xenografted tumors were visible at 18h p.i. with collateral, background radiation also being observed in non-target tissue. CONCLUSIONS:DUPA-6-Ahx-((64)Cu-NODAGA)-5-Ava-BBN(7-14)NH2] targeting vector, as described herein, is the first example of a dual GRPr-/PSMA-targeting radioligand for molecular of imaging prostate tumors. Detailed in vitro studies and microPET molecular imaging investigations of [DUPA-6-Ahx-((64)Cu-NODAGA)-5-Ava-BBN(7-14)NH2 in tumor-bearing mice indicate that further studies are necessary to optimize uptake and retention of tracer in GRPr- and PSMA-positive tissues. Published by Elsevier Inc.
Authors: Adam F Prasanphanich; Lauren Retzloff; Stephanie R Lane; Prasant K Nanda; Gary L Sieckman; Tammy L Rold; Lixin Ma; Said D Figueroa; Samantha V Sublett; Timothy J Hoffman; Charles J Smith Journal: Nucl Med Biol Date: 2009-02 Impact factor: 2.408
Authors: Prasant K Nanda; Usha Pandey; Brienne N Bottenus; Tammy L Rold; Gary L Sieckman; Ashley F Szczodroski; Timothy J Hoffman; Charles J Smith Journal: Nucl Med Biol Date: 2012-01-20 Impact factor: 2.408
Authors: Keith Graham; Ralf Lesche; Alexey V Gromov; Niels Böhnke; Martina Schäfer; Jorma Hassfeld; Ludger Dinkelborg; Georg Kettschau Journal: J Med Chem Date: 2012-10-24 Impact factor: 7.446
Authors: Sangeeta R Banerjee; Catherine A Foss; Mark Castanares; Ronnie C Mease; Youngjoo Byun; James J Fox; John Hilton; Shawn E Lupold; Alan P Kozikowski; Martin G Pomper Journal: J Med Chem Date: 2008-07-19 Impact factor: 7.446
Authors: Thomas L Collier; Kenneth Dahl; Nickeisha A Stephenson; Jason P Holland; Adam Riley; Steven H Liang; Neil Vasdev Journal: J Fluor Chem Date: 2018-03-05 Impact factor: 2.050
Authors: A P Kiess; S R Banerjee; R C Mease; S P Rowe; A Rao; C A Foss; Y Chen; X Yang; S Y Cho; S Nimmagadda; M G Pomper Journal: Q J Nucl Med Mol Imaging Date: 2015-07-24 Impact factor: 2.346